Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Update on Phase II study of hyper-CVAD with ponatinib in patients with Ph+ALL

Patrice Nasnas, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, describes the rationale and findings of a Phase II study investigating the combination of hyper-CVAD plus ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) . Dr Nasnas explains that the use of lower doses of ponatinib allowed to mitigate ponatinib-related toxicity, and overall, the combination was shown to induce deep and durable remissions. In addition, the trial reported no significant difference in overall survival (OS) between patients who did or did not undergo subsequent stem cell transplantation (SCT). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.